Matching articles for "cromolyn"
Treatment of Allergic Rhinitis and Allergic Conjunctivitis
The Medical Letter on Drugs and Therapeutics • March 31, 2025; (Issue 1725)
Initial treatment of allergic rhinitis (AR) depends
on the severity of symptoms and whether they are
intermittent or persistent (see Table...
Initial treatment of allergic rhinitis (AR) depends
on the severity of symptoms and whether they are
intermittent or persistent (see Table 1).
Comparison Table: Some Nasal Sprays for Seasonal Allergic Rhinitis (online only)
The Medical Letter on Drugs and Therapeutics • March 31, 2025; (Issue 1725)
...
View the Comparison Table: Some Nasal Sprays for Seasonal Allergic Rhinitis
Drugs for Allergic Rhinitis and Allergic Conjunctivitis
The Medical Letter on Drugs and Therapeutics • April 19, 2021; (Issue 1622)
The choice of drugs for treatment of allergic rhinitis
depends on the severity of symptoms and whether
they are intermittent or persistent (see Table...
The choice of drugs for treatment of allergic rhinitis
depends on the severity of symptoms and whether
they are intermittent or persistent (see Table 1).
Comparison Table: Some Oral Drugs for Allergic Rhinitis (online only)
The Medical Letter on Drugs and Therapeutics • April 19, 2021; (Issue 1622)
...
View the Comparison Table: Some Oral Drugs for Allergic Rhinitis
Comparison Table: Some Nasal Sprays for Allergic Rhinitis (online only)
The Medical Letter on Drugs and Therapeutics • April 19, 2021; (Issue 1622)
...
View the Comparison Table: Some Nasal Sprays for Allergic Rhinitis
Cetirizine Ophthalmic Solution (Zerviate) for Allergic Conjunctivitis
The Medical Letter on Drugs and Therapeutics • June 1, 2020; (Issue 1599)
A 0.24% ophthalmic solution of the second-generation
H1-antihistamine cetirizine (Zerviate – Eyevance) is now
available by prescription for treatment of ocular itching
associated with allergic...
A 0.24% ophthalmic solution of the second-generation
H1-antihistamine cetirizine (Zerviate – Eyevance) is now
available by prescription for treatment of ocular itching
associated with allergic conjunctivitis in patients ≥2
years old. Oral cetirizine (Zyrtec, and others), which is
used for treatment of allergic conjunctivitis and rhinitis,
has been available over the counter (OTC) for years.
OTC Drugs for Seasonal Allergies
The Medical Letter on Drugs and Therapeutics • April 22, 2019; (Issue 1570)
Patients with seasonal allergies often experience
nasal itching and congestion, sneezing, rhinorrhea,
and itchy, watery eyes. Oral, intranasal, and ophthalmic
preparations are widely available over the...
Patients with seasonal allergies often experience
nasal itching and congestion, sneezing, rhinorrhea,
and itchy, watery eyes. Oral, intranasal, and ophthalmic
preparations are widely available over the counter
(OTC) for relief of symptoms. Prescription products for
management of allergic rhinitis and allergic conjunctivitis
are reviewed separately.
Drugs for Allergic Disorders
The Medical Letter on Drugs and Therapeutics • May 8, 2017; (Issue 1520)
Allergic rhinitis can be classified as seasonal,
perennial, or episodic. It is often associated with
allergic conjunctivitis, rhinosinusitis, and asthma. H1-ANTIHISTAMINES — Oral – Oral...
Allergic rhinitis can be classified as seasonal,
perennial, or episodic. It is often associated with
allergic conjunctivitis, rhinosinusitis, and asthma.
H1-ANTIHISTAMINES — Oral – Oral second-generation H1-antihistamines are the preferred first-line treatment for relief of the itching, sneezing, and rhinorrhea that characterize mild-to-moderate allergic rhinitis. They are less effective for nasal congestion.
H1-ANTIHISTAMINES — Oral – Oral second-generation H1-antihistamines are the preferred first-line treatment for relief of the itching, sneezing, and rhinorrhea that characterize mild-to-moderate allergic rhinitis. They are less effective for nasal congestion.
Comparison Table: Some Nasal Sprays for Seasonal Allergic Rhinitis (online only)
The Medical Letter on Drugs and Therapeutics • May 8, 2017; (Issue 1520)
...
View the Comparison Table: Some Nasal Sprays for Seasonal Allergic Rhinitis
Drugs for Allergic Disorders
The Medical Letter on Drugs and Therapeutics • May 1, 2013; (Issue 129)
The use of drugs to prevent and control symptoms of
allergic disorders can be optimized when patients
avoid exposure to specific allergens and/or environmental
conditions that trigger or worsen their...
The use of drugs to prevent and control symptoms of
allergic disorders can be optimized when patients
avoid exposure to specific allergens and/or environmental
conditions that trigger or worsen their symptoms.
Drugs for Asthma
The Medical Letter on Drugs and Therapeutics • December 1, 2008; (Issue 76)
No truly new drugs have been approved for treatment of asthma since omalizumab (Xolair) in 2003, but some randomized controlled trials of older drugs have been published, and new guidelines have become...
No truly new drugs have been approved for treatment of asthma since omalizumab (Xolair) in 2003, but some randomized controlled trials of older drugs have been published, and new guidelines have become available.
Drugs for Some Common Eye Disorders
The Medical Letter on Drugs and Therapeutics • January 1, 2007; (Issue 53)
Drugs for glaucoma, age-related macular degeneration, bacterial and allergic conjunctivitis, and dry eyes are reviewed here. Ophthalmic drugs can have local and systemic adverse effects. In addition, for some...
Drugs for glaucoma, age-related macular degeneration, bacterial and allergic conjunctivitis, and dry eyes are reviewed here. Ophthalmic drugs can have local and systemic adverse effects. In addition, for some elderly patients, the complexity of self-administering numerous ophthalmic drugs may be the limiting factor in their ability to care for themselves.
Drugs for Asthma
The Medical Letter on Drugs and Therapeutics • May 1, 2005; (Issue 33)
Patients with mild, infrequent asthma symptoms may require only intermittent, asneeded use of an inhaled short-acting beta2-adrenergic agonist. Use of a short-acting beta2-agonist more than twice weekly, other...
Patients with mild, infrequent asthma symptoms may require only intermittent, asneeded use of an inhaled short-acting beta2-adrenergic agonist. Use of a short-acting beta2-agonist more than twice weekly, other than for exercise-induced bronchospasm, indicates a need for anti-inflammatory treatment. Inhaled corticosteroids are the most effective anti-inflammatory medication; leukotriene modifiers are less effective alternatives. If regular use of an inhaled corticosteroid in a low dose does not prevent symptoms, a long-acting beta2-agonist should be added; addition of a second drug is more effective than raising the dose of the inhaled steroid. A leukotriene modifier can also be used as the second drug. Omalizumab may be considered as adjunctive therapy for patients more than 12 years old who have allergic asthma not controlled by other drugs. A short course of oral corticosteroids may be useful for acute exacerbations. Treatment of acute severe asthma as a medical emergency is not included here; it has been reviewed elsewhere (ER McFadden Jr, Am J Respir Crit Care Med 2003; 168:740).
Drugs for Asthma
The Medical Letter on Drugs and Therapeutics • October 1, 2002; (Issue 2)
New drug formulations continue to be introduced for the treatment of asthma, and new studies on older drugs continue to change our perspectives on the management of this chronic inflammatory disease. Treatment...
New drug formulations continue to be introduced for the treatment of asthma, and new studies on older drugs continue to change our perspectives on the management of this chronic inflammatory disease. Treatment of asthma in the emergency department or hospital is not addressed here. More information on the diagnosis and treatment of asthma is available from Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma (Bethesda:NIH, 1997 and 2002 update; www.nhlbi.nih.gov).
New Drugs for Allergic Conjunctivitis
The Medical Letter on Drugs and Therapeutics • May 1, 2000; (Issue 1077)
Ophthalmic formulations of ketotifen fumarate (Zaditor), pemirolast potassium (Alamast) and nedocromil sodium (Alocril) have recently been approved by the FDA for use in adults and children with itching of the...
Ophthalmic formulations of ketotifen fumarate (Zaditor), pemirolast potassium (Alamast) and nedocromil sodium (Alocril) have recently been approved by the FDA for use in adults and children with itching of the eyes due to allergic conjunctivitis.
Drugs for Asthma
The Medical Letter on Drugs and Therapeutics • March 6, 2000; (Issue 1073)
Asthma is a chronic inflammatory disorder of the airways; inflammation caused by allergens, viral respiratory infections or other stimuli leads to bronchial hyperresponsiveness and obstruction of airflow....
Asthma is a chronic inflammatory disorder of the airways; inflammation caused by allergens, viral respiratory infections or other stimuli leads to bronchial hyperresponsiveness and obstruction of airflow. Anti-inflammatory drugs, particularly inhaled corticosteroids, are central to its management.
Drugs for Asthma
The Medical Letter on Drugs and Therapeutics • January 15, 1999; (Issue 1044)
Asthma is a chronic inflammatory disorder, with inflammation caused by allergens or other stimuli leading to bronchial hyperresponsiveness and obstruction of...
Asthma is a chronic inflammatory disorder, with inflammation caused by allergens or other stimuli leading to bronchial hyperresponsiveness and obstruction of airflow.
Fluticasone Propionate Nasal Spray for Allergic Rhinitis
The Medical Letter on Drugs and Therapeutics • January 20, 1995; (Issue 940)
An intranasal spray formulation of the corticosteroid fluticasone propionate (floo tik a sone; Flonase - Allen & Hanburys) has been approved by the US Food and Drug Administration for treatment of seasonal...
An intranasal spray formulation of the corticosteroid fluticasone propionate (floo tik a sone; Flonase - Allen & Hanburys) has been approved by the US Food and Drug Administration for treatment of seasonal and perennial allergic rhinitis in adults and children more than 12 years old.